PHOENIX, Ariz. — Aug. 26, 2011 — Waters Corporation (NYSE:WAT) today recognized the Center for Proteomics at the Translational Genomics Research Institute (TGen) as a Waters Center of Innovation.
In particular, Waters recognized Dr. Konstantinos Petritis, Head of TGen's Center for Proteomics, and his team for their leadership in the research of proteomics and biomarker discovery and verification.
In a ceremony at TGen's headquarters in Phoenix, Ariz., TGen President and Research Director Dr. Jeffrey Trent told TGen employees and representatives from Waters Corporation that TGen is moving with a great sense of urgency toward helping cancer patients.
"Whether it's through our discovery-based research or our clinical programs, our focus is to provide patient benefit as quickly as we can. My hope and expectation is that in many unique ways the Waters Centers of Innovation Program will help us accelerate our research and further our goal of providing personalized medicine to each patient in the future," said Dr. Trent.
"It was Dr. Trent's vision for translational medicine that led us to the relationship we have with TGen today. By formalizing our relationship with them we want to help TGen achieve its objectives and make personalized medicine a reality, partly by taking technology to the next level. I look forward to doing good science together for years to come," said Mark Groudas, Waters Sr. Vice President, Americas Business Operations.
TGen is now among an elite group of fewer than 20 partners worldwide that are part of the Waters Centers of Innovation. While most of the member institutes of this circle are well established, TGen (created in 2002) is one of the youngest organizations to be named.
"One of our core strengths is in biomarker discovery and verification. With the infrastructure we've put into place, we are making steady progress in the development of diagnostic and prognostic biomarkers for lung, colon, breast and pancreatic cancer as well as other diseases. We're thankful to Waters for their support of our programs, not just in terms of instrumentation, but in terms of their training, technical support and services," said Dr. Petritis.
Dr. Petritis is one of the few select researchers participating in Waters Center of Innovation Program. Others include Prof. Jeremy Nicholson, Imperial College London; Prof. John Engen, Northeastern University, Boston, Mass.; Prof. James Scrivens, University of Warwick, Coventry, UK; Prof. David Cowan of Kings College London; Prof. Arthur Moseley of Duke University, Durham, North Carolina; Prof. Julie Leary of the University of California – Davis; and Prof. Albert J. Fornace, Jr., Georgetown Lombardi Comprehensive Cancer Center, Washington, D.C.; Prof. Marcos Eberlin, University of Campinas, Brazil; Joseph Dalluge, University of Minnesota; Prof. Ganesh Anand, National University of Singapore; Dr. Chang Hsu, Future Fuels Institute; and Prof. Vladimir Shulaev, University of North Texas Department of Biological Sciences.
TGen's Center for Proteomics laboratory currently uses Waters® Synapt® G2 High Definition Mass Spectrometer and several ACQUITY UPLC®/Xevo® TQ-S Mass Spectrometers LC/MS/MS systems in support of its research.
About the Translational Genomics Research Institute (TGen)
The Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life changing results. Research at TGen is focused on helping patients with diseases such as cancer, neurological disorders and diabetes. TGen is on the cutting edge of translational research where investigators are able to unravel the genetic components of common and complex diseases. Working with collaborators in the scientific and medical communities, TGen believes it can make a substantial contribution to the efficiency and effectiveness of the translational process. TGen is affiliated with the Van Andel Research Institute in Grand Rapids, Michigan. For more information, visit: www.tgen.org.
About Waters Centers of Innovation Program
Waters Centers of Innovation Program recognizes and supports the efforts of scientists facilitating breakthroughs in health and life science research, food safety, environmental protection, sports medicine and many other areas. These leading scientists, in partnership with Waters, are using liquid chromatography and mass spectrometry to take research down new paths and help unlock the mysteries of science.
About Waters Corporation (www.waters.com)
For over 50 years, Waters Corporation (NYSE:WAT) has created business advantages for laboratory-dependent organizations by delivering practical and sustainable innovation to enable significant advancements in such areas as healthcare delivery, environmental management, food safety, and water quality worldwide. Pioneering a connected portfolio of separations science, laboratory information management, mass spectrometry and thermal analysis, Waters technology breakthroughs and laboratory solutions provide an enduring platform for customer success. With revenue of $1.64 billion in 2010 and 5,400 employees, Waters is driving scientific discovery and operational excellence for customers worldwide. Waters, Synapt, Xevo and ACQUITY, ACQUITY UPLC and UPLC are trademarks of Waters Corporation.
Waters Corporation:
Brian J. Murphy
Waters Corporation
Public Relations
+1 508-482-2614
brian_j_murphy@waters.com
TGen:
Steve Yozwiak
TGen Senior Science Writer
+1 602-343-8704
syozwiak@tgen.org